Companies: 49,246 Total Market Cap: 132591774254860.43

Zealand Pharma A/S

CPH-ZEAL
Healthcare Biotechnology
Rank #3506
Market Cap 4.42 B
Volume 169,151
Price 63.97
Change (%) 2.24%
Country or region Denmark Denmark

Zealand Pharma A/S's latest marketcap:

4.42 B

As of 05/20/2025, Zealand Pharma A/S's market capitalization has reached $4.42 B. According to our data, Zealand Pharma A/S is the 3506th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 4.42 B
Revenue (ttm) 8.38 M
Net Income (ttm) -178,327,705.60
Shares Out 70.69 M
EPS (ttm) -2.60
Forward PE 5.32
Ex-Dividend Date n/a
Earnings Date 05/08/2025
Market Cap Chart
Data Updated: 05/20/2025

Zealand Pharma A/S's yearly market capitalization.

Zealand Pharma A/S has seen its market value grow from kr8.77 B to kr29.41 B since 2020, representing a total increase of 235.50% and an annual compound growth rate (CAGR) of 31.77%.
Date Market Cap Change (%)
05/20/2025 kr29.41 B -43.72%
12/30/2024 kr50.55 B 132.03%
12/29/2023 kr21.79 B 110.16%
12/30/2022 kr10.37 B 65.31%
12/30/2021 kr6.27 B -28.46%
12/30/2020 kr8.77 B

Company Profile

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company specializing in the discovery, development, and commercialization of peptide-based medicines. Headquartered in Søborg, Denmark, the company operates in Denmark and the United States.

Key Focus Areas

The company's portfolio targets:

  • Gastrointestinal diseases
  • Metabolic disorders
  • Specialty disease areas with unmet medical needs

Products and Pipeline

Zealand Pharma offers innovative treatments, including:

  • Zegalogue: A single-use syringe or autoinjector for severe hypoglycemia treatment.
  • Dasiglucagon bi-hormone artificial pancreas systems: Combines insulin and dasiglucagon for advanced diabetes management.

The company's pipeline features promising candidates such as:

  • Dasiglucagon: Under development for congenital hyperinsulinism.
  • Glepaglutide: A long-acting GLP-2 analog in Phase III trials for short bowel syndrome.

Company Background

Founded in 1997, Zealand Pharma A/S has established itself as a leader in peptide-based therapeutics, addressing critical healthcare challenges worldwide.

Frequently Asked Questions

As of 05/20/2025, Zealand Pharma A/S (including the parent company, if applicable) has an estimated market capitalization of $4.42 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Zealand Pharma A/S global market capitalization ranking is approximately 3506 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Denmark
Founded 1997
IPO Date n/a
Employees 335
CEO Adam Steensberg
Sector Healthcare
Industry Biotechnology
Address Sydmarken 11
Søborg, 2860
Denmark
Website https://www.zealandpharma.com
People Also Watch
VRTX
440.66 2.24%
CSL Limited
156.10 2.24%
REGN
596.54 2.24%
KRX-207940
731.22 2.24%